Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial
Authors' conclusion
The Omnipod DASH System resulted in greater treatment satisfaction at 12 weeks in adults with type 1 diabetes using SMBG that was sustained after 24 weeks of device use without compromising sleep quality and fear of hypoglycemia. Improvements in glycemia were also observed.
Study context
- Population
- Adults with T1D on MDI or insulin pump therapy using self-monitoring blood glucose (SMBG), 4 diabetes centers in AustraliaAdults with T1D on MDI 40 · or insulin pump therapy 25
- Comparison
- Omnipod DASH System vs usual care
- Primary endpoint
- Treatment satisfaction: change in Diabetes Technology Questionnaire "current" score (ΔDTQ-current)
- Follow-up
- 12 weeks (study end)
Methodological detailsnonblinded, 1:1 randomisation, 4 diabetes centers in Australia, 12-week extension
- Nonblinded
- 1:1 randomisation
- 4 diabetes centers in Australia
- 12-week extension
Primary result
As reported in the abstract
ΔDTQ-current score
Omnipod
16.4
unspecified 21.2
Usual Care
0.0
unspecified 12.8
P < 0.001
Secondary outcomes
Other participant-reported outcomes (PROs) and HbA1c · 12 weeks (study end)
- Significantly greater improvements in other PROs and HbA1c with Omnipod
DTQ-current and other PROs, study end vs end extension · 24 weeks (end extension)
- Improvements comparing study end and end extension were similar
Change in TIR from baseline · 12 weeks (study end)
- Did not differ at study end
- −2.0 [12.7] %
Change in TIR from baseline · 24 weeks (end extension)
- Significantly greater at end extension
- 5.6 [10.9] %; P = .016
Original publication
Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial. J Clin Endocrinol Metab. Published 19 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →